Our previous study using the highly sensitive IMR immunoassay to measure several AD‐related biomarkers from plasma showed that combined elevated plasma Aβ1‐42 and tau protein levels could differentiate mild cognitive impairment from AD with a sensitivity and specificity of 0.80 and 0.82, respectively (Chiu et al., 2013). The gene discussed is MAPT; the disease is Cognitive impairment.